Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 7/20 | 0.49 |
| ▸ | AKT2 | P31751 | 6/20 | 0.49 |
| ▸ | TOP1 | P11387 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ADK | P55263 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14500994 | 0.88 | AKT1 (0.53) | AKT1AKT2DHODH | |
| SCHEMBL1350735 | 0.87 | AKT1 (0.52) | AKT1AKT2ADORA2AADORA1ADK | |
| SCHEMBL1352612 | 0.87 | AKT1 (0.45) | AKT1AKT2TOP1DHODHADK | |
| SCHEMBL5261709 | 0.87 | DHODH (0.49) | AKT1AKT2DHODHNPC1MEN1 | |
| Hydrochloric Acid SCHEMBL1350035 | 0.86 | AKT1 (0.51) | AKT1AKT2ADK | |
| SCHEMBL1350052 | 0.83 | AKT1 (0.48) | AKT1AKT2DHODHADK | |
| SCHEMBL1692394 | 0.81 | DHODH (0.44) | DHODHNPC1MEN1LMNATP53 | |
| SCHEMBL6004191 | 0.81 | DHODH (0.41) | DHODHADORA2AADORA1NPC1MEN1 | |
| SCHEMBL31520474 | 0.81 | FGFR1 (0.51) | TOP1ADORA2AADORA1NPC1MEN1 | |
| SCHEMBL5306884 | 0.81 | TOP1 (0.42) | AKT1AKT2TOP1DHODHNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778306-B | Synthesis method of 1, 8-naphthyridine derivative | 吉林化工学院 | 2024-01-26 | — | — | CN | disclosed |
| CN-112778306-A | Synthetic method of 1, 8-naphthyridine derivative | 吉林化工学院 | 2021-05-11 | — | — | CN | disclosed |
| EP-2593452-B1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| CN-103097385-B | IP receptor stimulating agent heterocyclic compound | 诺华股份有限公司 | 2016-08-03 | — | — | CN | disclosed |
| US-9132127-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-8754085-B2 | Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist | NOVARTIS AG (CH) | 2014-06-17 | — | — | US | disclosed |
| EP-2593452-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| WO-2012007539-A9 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012007539-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | PTGIR, ACVR1, PTGFR | AKT1 542/4885AKT2 627/4885TOP1 3847/4885 |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | PTGIR, ACVR1, PTGFR | AKT1 542/4885AKT2 627/4885TOP1 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.